desvenlafaxine succinate profile

Desvenlafaxine Succinate: A cyclohexanol and phenol derivative and metabolite of venlafaxine that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9800068
CHEMBL ID	1201728
SCHEMBL ID	272654
MeSH ID	M0521993

Synonym
o-desmethylvenlafaxine succinate
desvenlafaxine succinate
CHEMBL1201728
desvenlafaxine succinate anhydrous
dvs anhydrous
wy45233
AKOS005145772
HMS3264F16
S4112
448904-47-0
h9e1t0bi90 ,
butanedioic acid, compound with 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol (1:1)
1-((1rs)-2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl)cyclohexanol hydrogen butanedioate
CCG-213300
SCHEMBL272654
desvenlafaxine succinate anhydrous [mi]
desvenlafaxine succinate [who-dd]
c16h25no2.c4h6o4
dvs 233 succinate
o-desvenlafaxine succinate
4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol succinate
wy 45233 succinate
4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol succinate
HMS3652I16
o-desmethylvenlafaxine succinate hydrate
SW219514-1
HB1781
AS-17711
SB17445
HMS3885D05
desvenlafaxine succinate (tn)
D11619
Q27279801
butanedioic acid;4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
YSA90447
DTXSID701044359

Excerpt	Reference	Relevance
" The most commonly reported adverse events were nausea, insomnia, somnolence, dry mouth, dizziness, sweating, nervousness, anorexia, constipation, asthenia, and abnormal ejaculation/orgasm."	( A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. DeMartinis, NA; Entsuah, R; Manley, AL; Yeung, PP, 2007)	0.34
" The most common adverse events (incidence > or =10% in either desvenlafaxine group and twice the rate of placebo) were dry mouth, constipation, insomnia, decreased appetite, hyperhidrosis, and dizziness."	( Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Ganguly, R; Liebowitz, MR; Manley, AL; Padmanabhan, SK; Tourian, KA; Tummala, R, 2008)	0.35
" Desvenlafaxine groups reported significantly more adverse events compared with placebo during week 1 only."	( A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Archer, DF; Constantine, GD; Olivier, S; Pickar, JH; Seidman, L, 2009)	0.35
" Significantly more desvenlafaxine-treated subjects than placebo-treated subjects discontinued because of adverse events during week 1 only."	( Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Archer, DF; Constantine, GD; Dupont, CM; Olivier, S; Pickar, JH, 2009)	0.35
" Discontinuation rates due to adverse events (AEs) were 12% and 3% for desvenlafaxine and placebo, respectively (P=."	( A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. Feiger, AD; Padmanabhan, SK; Rosas, GR; Tourian, KA, 2009)	0.35
" Rates of taper/poststudy-emergent adverse events were summarized."	( Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Fava, M; Guico-Pabia, CJ; Montgomery, SA; Padmanabhan, SK; Tourian, KA, 2009)	0.35
"2%) placebo-treated patients discontinued due to adverse events."	( Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Guico-Pabia, CJ; Jiang, Q; Kornstein, SG; Musgnung, JJ; Reddy, S, 2010)	0.36
" Tolerability and safety were compared by an evaluation of reported adverse events."	( An indirect comparison of the efficacy and safety of desvenlafaxine and venlafaxine using placebo as the common comparator. Canny, LM; Coleman, KA; Meaney, JV; Palmer, TL; Radalj, LM; Xavier, VY, 2012)	0.38
" Potential ischemic cardiovascular events (coronary heart disease-related death, new-onset myocardial infarction or unstable angina requiring hospitalization, and unscheduled revascularization procedures) and cerebrovascular events (definite stroke or probable stroke) identified by investigator reports and periodic adverse event review based on Standardized medical dictionary for regulatory activities Query were reviewed by blinded adjudication boards."	( Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause. Archer, DF; Cheng, RF; Guico-Pabia, CJ; Hwang, E; Pinkerton, JV, 2013)	0.39
" Desvenlafaxine appears both safe and effective for treating hot flushes for up to 12 months."	( Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Hao, Y; Sun, Z; Zhang, M, 2013)	0.39
" Safety was evaluated according to adverse events, physical examination, vital signs, and laboratory assessments."	( An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. Baird-Bellaire, S; Behrle, JA; Nichols, AI; Parker, VD; Patat, A; Paul, J, 2013)	0.39
" The most common adverse events were nausea (n = 2, healthy subjects; n = 3, hepatically impaired subjects) and vomiting (n = 1, healthy subjects; n = 2, hepatically impaired subjects)."	( An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. Baird-Bellaire, S; Behrle, JA; Nichols, AI; Parker, VD; Patat, A; Paul, J, 2013)	0.39
" Desvenlafaxine was generally safe and well tolerated."	( Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. Bao, W; Clayton, AH; Dunlop, BW; Focht, K; Kornstein, SG; Musgnung, J; Ninan, PT; Ramey, T, 2013)	0.39
" Treatment-emergent adverse events (AEs), withdrawals because of AEs, laboratory tests, vital signs, and the Columbia Suicide-Severity Rating Scale (C-SSRS) were collected."	( Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder. Chiles, D; Findling, RL; Groark, J; Ramaker, S; Tourian, KA; Yang, L, 2014)	0.4
"Long-term (8 month) treatment with desvenlafaxine was generally safe and well tolerated in depressed children and adolescents."	( Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder. Chiles, D; Findling, RL; Groark, J; Ramaker, S; Tourian, KA; Yang, L, 2014)	0.4
" Safety and tolerability was evaluated by changes in routine laboratory parameters, vital signs, and adverse events reported by the subject and/or observed by the clinician."	( Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial. Chakraborty, S; Chatterjee, S; Ghosal, MK; Gupta, A; Maity, N; Sil, A, )	0.13
" However, the rate of desvenlafaxine treatment discontinuation because of adverse events was a significantly higher than placebo treated women and the risk ratios of adverse events like asthenia, hypertension, anorexia, constipation, diarrhea, dry mouth, nausea, dizziness, insomnia, somnolence and mydriasis were very high."	( Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies. Berhan, A; Berhan, Y, 2014)	0.4
"Desvenlafaxine is effective in the treatment of hot flashes but it is strongly associated with several adverse events and treatment discontinuation."	( Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor symptoms? A meta-analysis and meta-regression of randomized double-blind controlled studies. Berhan, A; Berhan, Y, 2014)	0.4
" Both the antidepressants were found to be safe and well tolerated."	( Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine. Bhatia, MS; Ghosh, R; Gupta, LK; Gupta, R; Tripathi, AK, 2015)	0.42
" Treatment with desvenlafaxine 50 and 100 mg/day was generally safe and well tolerated."	( An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder. Boucher, M; Carrasco, JL; Fayyad, R; Kornstein, SG; Mackell, J; McIntyre, RS; Prieto, R; Salas, M, 2016)	0.43
" Adverse events (AEs) were collected throughout the studies."	( Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials. Atkinson, S; Buckley, G; England, R; Jones, SR; Ramaker, S; Thurman, L; Wajsbrot, D, 2019)	0.51
"Desvenlafaxine 20 to 50 mg/d was generally safe and well tolerated with no new safety signals identified in children and adolescents with MDD who received up to 6 months of treatment in these studies."	( Safety, Tolerability, and Efficacy of Desvenlafaxine in Children and Adolescents with Major Depressive Disorder: Results from Two Open-Label Extension Trials. Atkinson, S; Buckley, G; England, R; Jones, SR; Ramaker, S; Thurman, L; Wajsbrot, D, 2019)	0.51

Excerpt	Reference	Relevance
" Analysis of variance showed no significant differences between the two venlafaxine regimens for peak concentration (Cmax), area under the curve during 24 hours (AUC0-24), trough concentration, or fluctuation ratio for venlafaxine or O-desmethylvenlafaxine in plasma."	( The pharmacokinetics of venlafaxine when given in a twice-daily regimen. Chiang, ST; Fruncillo, RJ; Parker, VD; Troy, SM, 1995)	0.29
" Other species differences were seen, including an elimination half-life of venlafaxine that was longer in dog and rhesus monkey (2-4 h) than in rodent (around 1 h)."	( Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Hicks, DR; Howell, SR; Scatina, JA; Sisenwine, SF, 1994)	0.29
" Thus, there were no clinically significant pharmacokinetic interactions between venlafaxine and lithium."	( Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. Boudino, FD; Chiang, ST; Hicks, DR; Parker, VD; Troy, SM, 1996)	0.29
"This single- and multiple-dose, nonrandomized, inpatient study was conducted to determine the effects of age and gender on the pharmacokinetic profiles of the antidepressant venlafaxine and its equally active metabolite, O-desmethylvenlafaxine."	( Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Chiang, ST; Derivan, AT; Klamerus, KJ; Parker, VD; Rudolph, RL, )	0.13
" This open-label study evaluated the effect of steady-state venlafaxine on CYP1A2-dependent metabolism, as measured by the pharmacokinetic disposition of caffeine, and urinary caffeine metabolite ratios (CMRs)."	( Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1999)	0.3
"An open-label study evaluated the effect of steady-state venlafaxine on the single-dose pharmacokinetic profile of risperidone, a CYP2D6 substrate; its active metabolite, 9-hydroxyrisperidone; and the total active moiety (risperidone plus 9-hydroxyrisperidone)."	( Effect of venlafaxine on the pharmacokinetics of risperidone. Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1999)	0.3
" Previous studies have documented the pharmacokinetic and pharmacodynamic profiles of DVS in male rats."	( Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Alfinito, PD; Chen, X; Deecher, DC; Huselton, C, 2006)	0.33
" Comparisons of AUC and Cmax between cytochrome P450 2D6 EMs and PMs were calculated using a Wilcoxon exact test."	( Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. Ahmed, S; Burczynski, ME; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Preskorn, S; Silman, H, 2009)	0.35
" This reduced pharmacokinetic variability of desvenlafaxine may translate into better uniformity of response for patients receiving desvenlafaxine versus venlafaxine, but additional studies are required to test this hypothesis."	( Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. Ahmed, S; Burczynski, ME; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Preskorn, S; Silman, H, 2009)	0.35
" The method herein described was superior to previous methods in sensitivity and sample throughput and successfully applied to clinical pharmacokinetic study of venlafaxine sustained-release capsule in healthy male volunteers after oral administration."	( Simultaneous quantification of venlafaxine and O-desmethylvenlafaxine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. Li, F; Li, N; Qin, F; Qin, T; Zhang, Y, 2010)	0.36
"Genetically driven variations in the level of cytochrome P450 (CYP) 2D6 metabolic activity have been shown to significantly affect the pharmacokinetic behaviour of medications that are substrates of this enzyme."	( Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Focht, K; Jiang, Q; Kane, CP; Nichols, AI; Preskorn, SH, 2011)	0.37
" Blood samples for pharmacokinetic analyses were collected during the 120 hours following administration of each study drug."	( Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Focht, K; Jiang, Q; Kane, CP; Nichols, AI; Preskorn, SH, 2011)	0.37
"To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-administrated to healthy volunteers."	( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012)	0.38
" Indinavir pharmacokinetic parameters were calculated by noncompartmental analysis using validated computer software."	( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012)	0.38
"No pharmacokinetic drug-drug interaction was demonstrated between venlafaxine XR and indinavir or between desvenlafaxine XR and indinvair."	( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012)	0.38
" Mechanistic pharmacokinetic simulations suggested that the low metabolite ratio was the result of combined poor metabolizer (PM) status of cytochrome P450 (CYP) 2C19 and CYP2D6."	( A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Ahlner, J; Boel, LW; Brock, B; Jornil, J; Nielsen, TS; Rosendal, I; Zackrisson, AL, 2013)	0.39
"The objectives of this study were to assess the pharmacokinetic profile, safety, and tolerability of desvenlafaxine in adults with chronic Child-Pugh class A, B, and C hepatic impairment."	( An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. Baird-Bellaire, S; Behrle, JA; Nichols, AI; Parker, VD; Patat, A; Paul, J, 2013)	0.39
" Median Tmax was similar for all groups (range, 6-9 hours)."	( An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. Baird-Bellaire, S; Behrle, JA; Nichols, AI; Parker, VD; Patat, A; Paul, J, 2013)	0.39
" The impact of venlafaxine on ticagrelor pharmacokinetic parameters was also investigated."	( Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Hsia, J; Kujacic, M; Teng, R, 2014)	0.4
" Plasma concentrations of ticagrelor, venlafaxine, and their metabolites (AR-C124910XX and O-desmethylvenlafaxine [ODV], respectively) were quantified for pharmacokinetic analyses."	( Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Hsia, J; Kujacic, M; Teng, R, 2014)	0.4
" Venlafaxine Cmax was increased by 22% in the presence of ticagrelor (121."	( Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects. Hsia, J; Kujacic, M; Teng, R, 2014)	0.4
" Period 1, day 1, subjects were administered tamoxifen 40 mg followed by 23 days of blood sampling for pharmacokinetic analyses."	( Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects. Braley, G; Liang, Y; Lubaczewski, S; Matschke, K; Nichols, AI; Ramey, T, 2014)	0.4
"To evaluate the ability of two biomarkers in reflecting venlafaxine pharmacokinetic variations, and to further examine their relationship with venlafaxine treatment outcomes."	( The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Choi, JY; Chung, MW; Ha, JH; Jiang, F; Kim, HD; Kim, YH; Lee, SY; Na, HS; Seo, DW; Shin, HJ, 2015)	0.42
"Two well-defined influencing factors: CYP2D6 genotypes and drug interactions were enriched into a three-period crossover study to produce venlafaxine pharmacokinetic variations: In each period, healthy CYP2D6 extensive metabolizers (EM group; n = 12) and CYP2D610/10 intermediate metabolizers (IM group; n = 12) were pretreated with clarithromycin (CYP3A4 inhibitor), or nothing (control), or clarithromycin + paroxetine (CYP3A4 + CYP2D6 inhibitors), before administration of a single-dose of 75 mg venlafaxine."	( The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Choi, JY; Chung, MW; Ha, JH; Jiang, F; Kim, HD; Kim, YH; Lee, SY; Na, HS; Seo, DW; Shin, HJ, 2015)	0.42
"A chiral LC-MS/MS method for the simultaneous analysis of desvenlafaxine (DVS) enantiomers in human plasma was developed and applied to a pharmacokinetic study on 12 Chinese healthy volunteers."	( [The enantioselective pharmacokinetic study of desvenlafaxine sustained release tablet in Chinese healthy male volunteers after oral administration]. Chen, XY; Chen, YX; Du, JB; Zhang, YF; Zhong, DF, 2015)	0.42
"To investigate the safety and pharmacokinetic profile of ascending doses of desvenlafaxine in children and adolescents with major depressive disorder."	( Pharmacokinetics and Tolerability of Single-Ascending Doses of Desvenlafaxine Administered to Children and Adolescents with Major Depressive Disorder. Chiles, D; Findling, RL; Groark, J; Nichols, AI; Ramaker, SA; Tourian, KA; Yang, L, 2016)	0.43
"To uncover pharmacokinetic interactions between venlafaxine and doxepin or mirtazapine in a naturalistic sample."	( Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. Fay, B; Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Schoretsanitis, G; Unholzer, S, 2018)	0.48
"Desvenlafaxine exposure in Korean and US populations was compared using population pharmacokinetic (PK) analysis."	( Population Pharmacokinetics of Desvenlafaxine: Pharmacokinetics in Korean Versus US Populations. Abbas, R; Liao, S; Nichols, AI, 2018)	0.48
"9 kg/m²), and high-BMI (≥30 kg/m²) groups, higher values of some pharmacokinetic variables in the lower BMI group did not remain significant after controlling for sex."	( Sex and body weight are major determinants of venlafaxine pharmacokinetics. Correll, CU; Fay, B; Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Schoretsanitis, G; Unholzer, S, 2018)	0.48
" We also investigated potential pharmacokinetic correlates of the four UKU categories by comparing patients complaining ADRs with those who did not."	( Pharmacokinetic correlates of venlafaxine: associated adverse reactions. Endres, K; Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Ridders, F; Schoretsanitis, G; Veselinovic, T, 2019)	0.51
" The pharmacokinetic profile of desvenlafaxine succinate at the clinically recommended dose of 50 mg in Chinese healthy subjects has been reported rarely."	( The Pharmacokinetics and Bioequivalence of Desvenlafaxine Succinate in Chinese Healthy Subjects Under Fasting and Fed States. Chen, Y; Hu, W; Wang, M; Wang, Y; Yang, Y; Zhang, X, 2023)	0.91

Excerpt	Reference	Relevance
"A number of antidepressants inhibit the activity of the cytochrome P450 2D6 enzyme system, which can lead to drug-drug interactions."	( An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Burczynski, ME; Connolly, SM; Fatato, P; Guico-Pabia, C; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Pedersen, R, 2008)	0.35
" In conclusion, the high suicide potential of VEN in combination with the high prevalence of drugs causing adverse interactions could be the reason for the observed high FTI."	( Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Launiainen, T; Ojanperä, I; Rasanen, I; Vuori, E, 2011)	0.37
"No pharmacokinetic drug-drug interaction was demonstrated between venlafaxine XR and indinavir or between desvenlafaxine XR and indinvair."	( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012)	0.38
" During period 2, subjects received desvenlafaxine 100 mg/d for 28 days; a single dose of tamoxifen 40 mg was administered with desvenlafaxine 100 mg on day 7, followed by 23 days of blood sampling."	( Open-label, 2-period sequential drug interaction study to evaluate the effect of a 100-mg dose of desvenlafaxine on the pharmacokinetics of tamoxifen when coadministered in healthy postmenopausal female subjects. Braley, G; Liang, Y; Lubaczewski, S; Matschke, K; Nichols, AI; Ramey, T, 2014)	0.4
" The technique has potential to identify drug-drug interaction involving VX and O-DVX enantiomers while administering indinivar therapy."	( Development of an enantioselective assay for simultaneous separation of venlafaxine and O-desmethylvenlafaxine by micellar electrokinetic chromatography-tandem mass spectrometry: Application to the analysis of drug-drug interaction. Eap, CB; Jann, M; Liu, Y; Shamsi, SA; Vandenberg, C, 2015)	0.42

Excerpt	Reference	Relevance
"The comparative bioavailability of the novel antidepressant venlafaxine and its pharmacologically active metabolite O-desmethylvenlafaxine was assessed when venlafaxine was given orally twice daily (75 mg bid) or 3 times daily (50 mg tid)."	( The pharmacokinetics of venlafaxine when given in a twice-daily regimen. Chiang, ST; Fruncillo, RJ; Parker, VD; Troy, SM, 1995)	0.29
" Absolute bioavailability was low in rat and rhesus monkey (12."	( Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Hicks, DR; Howell, SR; Scatina, JA; Sisenwine, SF, 1994)	0.29
" Bioavailability is high at 80% after oral administration and is not affected by food."	( Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. Guico-Pabia, CJ; Kane, C; Musgnung, J; Ninan, PT; Pitrosky, B; Reddy, S, 2010)	0.36
"06 mmol/kg, orally) rapidly penetrated rat brain and hypothalamus, translated into desvenlafaxine within 1 h, and demonstrated higher bioavailability and better pharmacokinetic properties than desvenlafaxine succinate (DVS)."	( Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. Gai, Y; Hou, J; Jiang, WL; Li, YX; Meng, Q; Tian, JW; Xing, Y; Zhong, Y; Zhu, HB, 2011)	0.37
" However, in the periphery, venlafaxine treatment significantly reduced the topotecan oral bioavailability by nearly 40%, whereas the impact of desvenlafaxine on topotecan plasma levels was more modest (23%)."	( Effect of venlafaxine and desvenlafaxine on drug efflux protein expression and biodistribution in vivo. Bachmeier, C; Beaulieu-Abdelahad, D; Levin, GM; Mullan, M; Reed, J, 2013)	0.39
" The four compounds producing the highest relative bioavailability of ODV in rat (compounds 1c, 1e, 1n, 1o) were then studied to evaluate their brain uptake."	( Phenolic esters of O-desmethylvenlafaxine with improved oral bioavailability and brain uptake. Fawcett, JP; Gu, J; Li, Y; Sun, T; Yang, H; Yang, Y; Yang, Z; Zhang, Y; Zhao, S, 2013)	0.39
" If their bioavailability is increased, this communication and the state of homeostasis may be disrupted."	( NMR-based metabonomic analysis of normal rat urine and faeces in response to (±)-venlafaxine treatment. García-Pérez, I; Meléndez-Camargo, ME; Serrano-Contreras, JI; Zepeda-Vallejo, LG, 2016)	0.43

Excerpt	Relevance	Reference
" In conclusion, the disposition of venlafaxine and O-desmethylvenlafaxine is markedly altered in renal disease; therefore dosage adjustment is warranted for patients with creatinine clearance values below 30 ml/min."	( The effect of renal disease on the disposition of venlafaxine. Blum, RA; Chiang, ST; Parker, VD; Schultz, RW; Troy, SM, 1994)	0.29
" Exposure of venlafaxine decreased with repeated dosing in mouse and rat, but was unchanged in dog."	( Pharmacokinetics of venlafaxine and O-desmethylvenlafaxine in laboratory animals. Hicks, DR; Howell, SR; Scatina, JA; Sisenwine, SF, 1994)	0.29
" We conclude that venlafaxine dosage adjustments for age or gender are not necessary based on pharmacokinetics."	( Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Chiang, ST; Derivan, AT; Klamerus, KJ; Parker, VD; Rudolph, RL, )	0.13
" Samples were collected before and for 24 hours after caffeine dosing for the determination of caffeine in plasma and 1,7-dimethylxanthine, 3,7-dimethylxanthine, 1,7-dimethyluric acid (17U), 1-methylxanthine (1X) and 1-methyluric acid (1U), and 5-acetylamino-6-amino-3-methyluracil (AAMU) in urine."	( Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1999)	0.3
" Thirty healthy subjects received a 1 mg oral dose of risperidone before and after venlafaxine dosing to steady state."	( Effect of venlafaxine on the pharmacokinetics of risperidone. Albano, D; Amchin, J; Klockowski, PM; Taylor, KP; Zarycranski, W, 1999)	0.3
"Considering its modest sample size, naturalistic design and limited observation period, the present study provided preliminary indication that earlier clinical response may occur with higher V+ODV plasma level, extending previous dose-response studies."	( Time course of clinical response to venlafaxine: relevance of plasma level and chirality. Balant, LP; Balant-Gorgia, AE; Bertschy, G; Gex-Fabry, M; Rudaz, S; Veuthey, JL, 2004)	0.32
" Advantages compared to other antidepressants include once daily dosing at effective doses, no CYP450 metabolism and low drug-drug interactions."	( Desvenlafaxine succinate for the treatment of major depressive disorder. Lohoff, FW; Rickels, K, 2008)	0.35
" Clearance rates are reduced in the elderly, those with severe renal dysfunction and those with moderate to severe hepatic dysfunction, which may require dosage adjustments."	( Desvenlafaxine succinate for major depressive disorder. Hazra, M; Pollock, BG; Sproule, BA, 2008)	0.35
" The CYP2D6 substrate desipramine (50 mg) was administered alone on day 1 and coadministered on day 6 of dosing with either desvenlafaxine or paroxetine."	( The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. Ahmed, S; Fatato, P; Isler, JA; Jiang, Q; Nichols, AI; Patroneva, A; Paul, J; Pedersen, RD; Shenouda, M, 2009)	0.35
" Current evidence indicates that DVS has proven efficacy, acceptable safety and tolerability profiles, convenient once-daily dosing and minimal impact on cytochrome P450 enzyme system and adverse event-prone neuroreceptors."	( Desvenlafaxine: a new antidepressant or just another one? Pae, CU, 2009)	0.35
" Alternate-day dosing should be implemented in patients with severe renal impairment (creatinine clearance, < or =30 mL/min) and those with end-stage renal disease."	( Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Cassagnol, M; Perry, R, 2009)	0.35
"05); there was no evidence of a dose-response relationship."	( Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. Guico-Pabia, CJ; Jiang, Q; Kornstein, SG; Soares, CN; Thase, ME, 2009)	0.35
", make a patient an outlier on the usual dose-response curve)."	( Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters. Preskorn, SH, 2010)	0.36
" Significant points of difference, compared with venlafaxine, are once-daily dosing and the achievement of steady-state plasma concentrations within 4 to 5 days."	( Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. Masand, PS; Pae, CU; Patkar, AA; Seo, HJ; Sohi, MS, 2010)	0.36
"HAM-D (17) effect sizes were negative (favoured placebo) for higher desvenlafaxine doses (200-400 mg/d) at week 1, but were positive for all doses after week 2, with no clear dose-response pattern."	( HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder. Bech, P; Boyer, P; Germain, JM; Haudiquet, V; Padmanabhan, K; Pitrosky, B; Tourian, KA, 2010)	0.36
" Trials of citalopram and escitalopram were associated with reports of persistent nausea and gastric reflux unresolved by changes in dosing schedule or positioning."	( Antidepressant-mediated gastroesophageal reflux disease. Brahm, NC; Kelly-Rehm, MC, 2011)	0.37
" In dose-response assays, oral administration of TP1 reduced the time of immobility in a dose-dependent manner during tail suspension test and forced swimming test (FST)."	( Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. Gai, Y; Hou, J; Jiang, WL; Li, YX; Meng, Q; Tian, JW; Xing, Y; Zhong, Y; Zhu, HB, 2011)	0.37
" Currently available data show that DESV has proven efficacy, acceptable safety and tolerability profiles, convenient once-daily dosing and minimal impact on the cytochrome P450 enzyme system in patients with MDD."	( Desvenlafaxine in the treatment of major depressive disorder. Pae, CU, 2011)	0.37
" Starting on day 2, venlafaxine XR was dosed at 37."	( Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir. Jann, MW; Momary, K; Penzak, SR; Spratlin, V; Turner, D; VanDenBerg, C; Wright, A; Zhang, H, 2012)	0.38
" It is concluded that sex, age and smoking should be considered for optimal dosing of patients with VEN."	( The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions. Deckert, J; Greiner, C; Haen, E; Hiemke, C; Jabs, B; Pfuhlmann, B; Unterecker, S, 2012)	0.38
"Patients with major depression were randomized to either active or placebo pindolol 20 mg retard daily dosage and concomitantly treated with venlafaxine for 19 days."	( A short-term double-blind randomized controlled pilot trial with active or placebo pindolol in patients treated with venlafaxine for major depression. Bech, P; Lunde, M; Martiny, K; Plenge, P, 2012)	0.38
"Consistent with other clinical studies, desvenlafaxine 50▒mg/day demonstrated antidepressant efficacy and appears to be the minimally effective dosage for MDD."	( Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients. Hwang, E; Iwata, N; Mele, L; Tourian, KA; Vialet, C, 2013)	0.39
" This was a phase 3, multicenter, 10-month, open-label study with flexible dosing of desvenlafaxine (25, 50, 100 mg/day)."	( A 10-month, open-label evaluation of desvenlafaxine in Japanese outpatients with major depressive disorder. Ii, Y; Tourian, K; Wang, Y, 2013)	0.39
" The developed and validated method can be successfully applied for the bioequivalence/pharmacokinetic studies of desvenlafaxine in pharmaceutical dosage forms."	( Novel LC- ESI-MS/MS method for desvenlafaxine estimation human plasma: application to pharmacokinetic study. Dannana, GS; Kancharla, PK; Kondru, VG, 2016)	0.43
"Pharmacogenetic-based dosing support tools have been developed to personalize antidepressant-prescribing practice."	( Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study. Berk, M; Bousman, CA; Byron, K; Müller, DJ; Ng, CH; Singh, AB, 2017)	0.46
" A positive correlation was detected between body weight and daily dosage (rs=0."	( Sex and body weight are major determinants of venlafaxine pharmacokinetics. Correll, CU; Fay, B; Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Schoretsanitis, G; Unholzer, S, 2018)	0.48
" Hence, a different dosing strategy is required among smoking and nonsmoking patients."	( Analysis of smoking behavior on the pharmacokinetics of antidepressants and antipsychotics: evidence for the role of alternative pathways apart from CYP1A2. Deckert, J; Hommers, LG; Menke, A; Samanski, L; Scherf-Clavel, M; Unterecker, S, 2019)	0.51
" Unlike the selective serotonin (5-HT) reuptake inhibitors (SSRIs), most of these antidepressants have an ascending rather than a flat dose-response curve."	( Serotonin and Norepinephrine Reuptake Inhibitors. Shelton, RC, 2019)	0.51
" Venlafaxine daily dosage did not differ between responders and non-responders (217."	( Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. Correll, CU; Endres, K; Gründer, G; Haen, E; Hiemke, C; Paulzen, M; Ridders, F; Schoretsanitis, G, 2019)	0.51
"Median daily dosage of venlafaxine was 75 mg (range 37."	( Pregnancy exposure to venlafaxine-Therapeutic drug monitoring in maternal blood, amniotic fluid and umbilical cord blood and obstetrical outcomes. Augustin, M; Franz, C; Gründer, G; Paulzen, M; Schoretsanitis, G; Stingl, JC, 2020)	0.56
" This finding is of clinical relevance when adjusting dosing of CYP2D6 substrates during comedication with BUP."	( Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression. Arnestad, M; Haslemo, T; Hole, K; Molden, E, )	0.13
"This study strongly suggests that TDM could represent a more appropriate tool than the oral dosage to optimise the treatment with VEN."	( Venlafaxine and O-desmethylvenlafaxine serum levels are positively associated with antidepressant response in elder depressed out-patients. Conca, A; De Donatis, D; Florio, V; Giupponi, G; Mercolini, L; Porcelli, S; Serretti, A; Zernig, G, 2022)	0.72

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	10 (3.11)	18.2507
2000's	70 (21.74)	29.6817
2010's	205 (63.66)	24.3611
2020's	37 (11.49)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	90 (26.32%)	5.53%
Reviews	51 (14.91%)	6.00%
Case Studies	29 (8.48%)	4.05%
Observational	4 (1.17%)	0.25%
Other	168 (49.12%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (74)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A 10 Month Open-Label Evaluation Of The Long-Term Safety Of DVS-233 SR In Outpatients With Major Depressive Disorder. [NCT01309542]	Phase 3	1,403 participants (Actual)	Interventional	2003-08-31	Completed
A Randomized, Open-Label, 2-Treatment, 2-Sequence, 2-Period Crossover Trial to Assess the Bioequivalence of 80 mg LY03005 to 50 mg Pristiq After Single Dose Administration Under Fasting Conditions to Healthy Subjects [NCT03733574]	Phase 1	56 participants (Actual)	Interventional	2018-06-19	Completed
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLUOXETINE-REFERENCED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF DESVENLAFAXINE SUCCINATE SUSTAINED RELEASE (DVS SR) IN THE TREATMENT OF CHILDREN AND ADOLESCENT O [NCT01372150]	Phase 3	340 participants (Actual)	Interventional	2011-11-17	Completed
Phenotype Predictors of Cognitive Outcomes in Geriatric Depression [NCT05273996]	Phase 4	75 participants (Anticipated)	Interventional	2021-09-28	Recruiting
Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Females and Males [NCT01101152]	Phase 1	20 participants (Anticipated)	Interventional	2010-04-30	Recruiting
A Multi-center, Randomized, Double-blind, Double-simulation, Duloxetine Hydrochloride Enteric-coated Positive-control Phase III Study of Desvenlafaxine Succinate Sustained-Release in the Treatment of Major Depressive Disorder. [NCT04364997]	Phase 3	420 participants (Actual)	Interventional	2020-06-18	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03005 [NCT02055300]	Phase 1	88 participants (Actual)	Interventional	2014-02-28	Completed
An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression [NCT02200406]	Phase 4	18 participants (Actual)	Interventional	2014-07-31	Completed
An Open Label, Non-interventional Study Of The Safety Of Desvenlafaxine Succinate (Pristiq) In The Treatment Of Major Depressive Disorder (Mdd) And Vasomotor Symptoms (Vms) Associated With Menopause In Filipino Adult Patients: A Post Marketing Surveillanc [NCT01353963]		13 participants (Actual)	Observational	2012-03-31	Terminated
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury [NCT02320240]		3,255,526 participants (Actual)	Observational	2013-06-30	Completed
A Retrospective Study To Evaluate The Current Utilization Of Desvenlafaxine Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder [NCT01221935]		2,701 participants (Actual)	Observational	2009-09-30	Completed
A Randomized, Open-label, Cross-over, 2-period Study to Assess the Relative Bioavailability Between 80 mg LY03005 Versus 50 mg Desvenlafaxine Comparator (Pristiq®) Under Fasting Condition After Single Dose Administration in Healthy Subjects [NCT03357796]	Phase 1	20 participants (Actual)	Interventional	2017-11-27	Completed
A Randomized, Double-Blind, Parallel Group Study To Compare Discontinuation Symptoms In Abrupt Discontinuation Versus A 1-Week Tapering Regimen In Subjects With MDD Treated For 24 Weeks With Open-Label 50 mg DVS SR Formulation [NCT01056289]	Phase 4	480 participants (Actual)	Interventional	2010-03-31	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pregabalin-Referenced, Parallel-Group, Adaptive Design Study of DVS SR in Adult Female Outpatients With Fibromyalgia Syndrome [NCT00696787]	Phase 2	125 participants (Actual)	Interventional	2008-06-30	Terminated
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Desvenlafaxine Succinate Sustained Release Administered Orally to Healthy Chinese Subjects. [NCT00818155]	Phase 1	36 participants (Actual)	Interventional	2009-01-31	Completed
Effects of Genetic Polymorphisms in the Organic Cation Transporter OCT1 on Cellular Uptake and Metabolism of Antidepressants and Other Organic Cationic Drugs [NCT02054299]	Phase 1	48 participants (Actual)	Interventional	2013-04-30	Completed
Desvenlafaxine for the Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen: a Randomized, Double-blind, Placebo-controlled Study [NCT02819921]	Phase 4	59 participants (Actual)	Interventional	2017-11-10	Terminated(stopped due to Difficulty in Recruiting Research Participants)
Final Report: Multicenter, Open-Label, Safety, Tolerability, And Pharmacokinetic Study To Evaluate Single Ascending Doses And Subsequent Short-Term Administration Of Fixed Doses Of DVS SR Tablets In The Treatment Of Child And Adolescent Outpatients With M [NCT00619619]	Phase 2	59 participants (Actual)	Interventional	2008-02-29	Completed
A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms [NCT06049797]		1,000 participants (Anticipated)	Observational	2023-11-15	Recruiting
A Phase 3, Randomized, Double-Blind Study Comparing the Efficacy and Safety of SAGE-217 Plus an Antidepressant Versus Placebo Plus an Antidepressant in Adults With Major Depressive Disorder [NCT04476030]	Phase 3	440 participants (Actual)	Interventional	2020-11-09	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Duloxetine-Referenced, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50mg, 100mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depress [NCT00384033]	Phase 3	638 participants (Actual)	Interventional	2006-09-30	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Efficacy And Safety Of 2 Fixed Doses (10 And 50 mg/Day) Of DVS SR Tablets In Adult Outpatients With Major Depressive Disorder [NCT00863798]	Phase 3	682 participants (Actual)	Interventional	2009-04-30	Completed
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate Functional Outcome In Outpatients With Major Depressive Disorder Treated With Desvenlafaxine Succinare Sustained Release [NCT00824291]	Phase 3	437 participants (Actual)	Interventional	2009-02-28	Completed
A Double-Blind, Randomized, Placebo-Controlled Study Assessing The Safety And Efficacy Of DVS SR For The Treatment Of Vasomotor Symptoms Associated With Menopause [NCT00683800]	Phase 3	2,186 participants (Actual)	Interventional	2008-06-30	Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder [NCT00797966]	Phase 2	850 participants (Actual)	Interventional	2009-05-31	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (25 and 50 mg/Day) of DVS SR Tablets in Adult Outpatients With Major Depressive Disorder [NCT00798707]	Phase 3	709 participants (Actual)	Interventional	2008-12-31	Completed
Phase 1, Open-Label, Randomized, Single-Dose, 4-Treatment, 4-Period Crossover Bioequivalence Study Comparing 25 Mg and 50 Mg Formulations of DVS-233 SR and Investigate Food Effect on 50 Mg Formulations of DVS-233 SR Tablet Under Fed and Fasted Conditions [NCT01190514]	Phase 1	41 participants (Actual)	Interventional	2010-09-30	Completed
A Multicenter, Parallel-Group, Randomized, 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of 50 mg Of DVS SR In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder [NCT01121484]	Phase 4	439 participants (Actual)	Interventional	2010-06-30	Completed
Desvenlafaxine Succinate in Major Depressive Disorder: Effects on Structural and Functional Imaging, Cognition, and Functional Outcomes in Midlife Women and Men [NCT00888862]	Phase 3	90 participants (Anticipated)	Interventional	2009-06-30	Recruiting
The Effect of Dose Titration and Dose Tapering on the Tolerability of DVS SR in Women With Vasomotor Symptoms Associated With Menopause: The PRIMMUS (PRIstiq for Managing Menopause and Understanding Symptoms) Study [NCT00401245]	Phase 3	500 participants (Actual)	Interventional	2006-12-31	Completed
An Open-Label, 2-Period Sequential Drug Interaction Study To Evaluate The Effect Of A 100 Mg Dose Of Desvenlafaxine SR On The Pharmacokinetics Of Aripiprazole When Coadministered In Healthy Subjects [NCT01188668]	Phase 4	38 participants (Actual)	Interventional	2010-08-31	Completed
A 10-Month Open-Label Evaluation Of The Long-Term Safety Of Desvenlafaxine Succinate Sustained Release In Japanese Adults With Major Depressive Disorder [NCT00831415]	Phase 3	304 participants (Actual)	Interventional	2009-03-31	Completed
A Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled Study Followed by a 6-month Open-label Extension to Evaluate the Efficacy and Safety of DVS SR in Peri- and Postmenopausal Women With Major Depressive Disorder [NCT00369343]	Phase 3	381 participants (Actual)	Interventional	2006-09-30	Completed
6-Month, Multicenter, Open-Label, Flexible-Dose Study To Evaluate Safety, Efficacy, And Tolerability Of Desvenlafaxine Succinate Sustained-Release Tablets In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder [NCT00669110]	Phase 2	40 participants (Actual)	Interventional	2008-05-31	Completed
An 8-week Open-Label Flexible-Dose Study Of Desvenlafaxine as Monotherapy In The Treatment Of Dysthymia [NCT01948895]		30 participants (Actual)	Interventional	2012-08-31	Completed
A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression [NCT01974934]	Phase 4	30 participants (Anticipated)	Interventional	2013-12-31	Recruiting
Efficacy of Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment on Prefrontality in Patients With Generalized Anxiety Disorder (GAD) and Other Comorbidities [NCT01975480]	Phase 4	29 participants (Actual)	Interventional	2013-01-31	Completed
A Double-Blind,Venlafaxine-Controlled Study of Efficacy and Safety of Sustained-Release Desvenlafaxine Hydrochloride in the Treatment of Major Depressive Disorder [NCT01977378]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2013-10-31	Recruiting
A Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Before and After Treatment With Desvenlafaxine [NCT02859103]	Phase 4	56 participants (Actual)	Interventional	2017-06-01	Completed
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]		1,037,352 participants (Actual)	Observational	2016-09-30	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy, Safety And Tolerability Of Desvenlafaxine Succinate Sustained-release (Dvs Sr) In The Treatment Of Children And Adolescent Outpatients With Major D [NCT01371734]	Phase 3	363 participants (Actual)	Interventional	2011-08-31	Completed
An Open-Label, 2-Period Sequential Drug Interaction Study To Evaluate The Effect Of A 100 Mg Dose Of Desvenlafaxine SR On The Pharmacokinetics Of Tamoxifen When Co-Administered In Healthy Post-Menopausal Female Subjects [NCT01189500]	Phase 4	30 participants (Actual)	Interventional	2010-08-31	Completed
A Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal, Parallel Group Study To Evaluate The Efficacy And Safety Of 50 mg/Day Of DVS SR In Adult Outpatients With Major Depressive Disorder [NCT00887224]	Phase 3	874 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers [NCT00329186]	Phase 3	14 participants (Actual)	Interventional	2006-05-31	Completed
A Multicenter, Randomized, 8-Week Double-Blind Acute Phase Followed By a 6-Month Continuation Phase (Open-Label Or Double-Blind) Study to Evaluate the Efficacy, Safety, and Tolerability of DVS SR Versus Escitalopram in Postmenopausal Women With Major Depr [NCT00406640]	Phase 3	595 participants (Actual)	Interventional	2006-12-31	Completed
White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study [NCT01492621]	Phase 4	40 participants (Anticipated)	Interventional	2011-11-30	Recruiting
A 12-Month Open-Label Evaluation of the Long-Term Safety of DVS-233 SR in Outpatients With Major Depressive Disorder [NCT00452595]	Phase 3	0 participants	Interventional	2004-01-31	Completed
An Open-Label, Two-Period, Sequential Drug Interaction Study to Evaluate the Effect of Multiple Doses of Desvenlafaxine Succinate Sustained Release (DVS SR) on the Pharmacokinetics of Midazolam When Coadministered in Healthy Subjects [NCT00952653]	Phase 4	28 participants (Actual)	Interventional	2010-06-30	Completed
A Randomized, Open-Label, 3-Period Crossover Study to Evaluate the Effect of Multiple Doses of DVS SR and Paroxetine on the CYP2D6 Biotransformation of Codeine to Morphine in Healthy Subjects. [NCT00456898]	Phase 1	40 participants	Interventional	2007-01-31	Completed
A Randomized, Open-Label, Single-Dose Study to Assess the Relative Bioavailability of LY03005 Oral Tablets Versus Pristiq Oral Tablets Under Fasting Conditions in Healthy Subjects [NCT02988024]	Phase 1	20 participants (Actual)	Interventional	2016-12-07	Completed
A Randomized, Open-Label, Cross-Over Drug Interaction Study to Evaluate the Effects of Desvenlafaxine (DVS SR) and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects [NCT00329147]	Phase 3	20 participants (Anticipated)	Interventional	2006-05-31	Completed
A Randomized, Open-Label, Single-Dose Parallel Group Study of the Pharmacokinetic Profile, Safety, and Tolerability of 25- and 50-mg Desvenlafaxine Sustained Release (DVS SR) in Healthy Subjects [NCT00440427]	Phase 1	12 participants	Interventional	2007-02-28	Completed
A Pilot Study of Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine [NCT01527786]	Phase 3	25 participants (Actual)	Interventional	2010-11-30	Completed
Ascending, Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of DVS SR Administered Orally to Healthy Japanese Female Subjects [NCT00397176]	Phase 1	32 participants	Interventional	2006-11-30	Completed
A Placebo-controlled Study of MD-120 in Patients With Depression [NCT04345471]	Phase 3	615 participants (Actual)	Interventional	2020-05-18	Completed
A Randomized, Open-Label, Crossover, Drug Interaction Study to Evaluate the Effects of DVS SR And Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects [NCT00366652]	Phase 3	20 participants (Anticipated)	Interventional	2006-09-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005 [NCT02271412]	Phase 1	58 participants (Actual)	Interventional	2014-10-31	Completed
A 6-Month Open-Label Extension Study of the Long-Term Safety of DVS SR in Outpatients With Fibromyalgia Syndrome. [NCT00424892]	Phase 2/Phase 3	600 participants	Interventional		Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (50 mg, 100 mg) of Desvenlafaxine Sustained-Release Tablets in Adult Outpatients With Major Depressive Disorder [NCT00300378]	Phase 3	480 participants (Anticipated)	Interventional	2006-03-31	Completed
A Phase 1, Randomized, Subject- and Investigator-Blind, Placebo-Controlled, Parallel-Group, Single and Multiple-Dose Study of Desvenlafaxine in Korean Healthy Subjects [NCT01443208]	Phase 1	36 participants (Actual)	Interventional	2011-11-30	Completed
Neurocognition and Work Productivity in Major Depressive Disorder [NCT01468610]		47 participants (Actual)	Interventional	2012-01-31	Completed
A Randomized, Open-Label, 2-Period, Crossover Trial to Assess the Relative Bioavailability of 80 mg LY03005 After Single Dose Administration to Healthy Subjects Under Fed Versus Fasted Conditions [NCT03822065]	Phase 1	34 participants (Actual)	Interventional	2019-01-16	Completed
A 9-Month Open-Label Extension Study of the Long-Term Safety of DVS SR in Outpatients With Pain Associated With Diabetic Peripheral Neuropathy [NCT01050218]	Phase 3	237 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to Business reasons)
A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Pristiq® (Desvenlafaxine) Extended-Release Tablets in Generalized Social Anxiety Disorder [NCT01316302]	Phase 4	63 participants (Actual)	Interventional	2011-04-30	Completed
Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data [NCT04446039]		405,349 participants (Actual)	Observational	2022-07-04	Completed
A Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of DVS SR for Treatment of Vasomotor Symptoms Associated With Menopause [NCT00369434]	Phase 3	450 participants (Anticipated)	Interventional	2006-06-30	Completed
A Phase IV, Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy of 2 Fixed Doses (50 and 100 mg/Day) of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depres [NCT01432457]	Phase 4	924 participants (Actual)	Interventional	2011-10-31	Completed
Effects of Treatment on Decision-making in Major Depression [NCT01916824]	Phase 4	53 participants (Actual)	Interventional	2013-08-31	Completed
A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers [NCT00727064]	Phase 1	14 participants (Actual)	Interventional	2008-06-30	Completed
Desvenlafaxine (Pristiq) vs. Placebo in the Treatment of Chronic Depression [NCT01537068]	Phase 4	59 participants (Actual)	Interventional	2012-02-29	Completed
Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis [NCT02330679]	Phase 4	61 participants (Anticipated)	Interventional	2014-12-31	Recruiting
A Randomised, Double-blind, Parallel-group, Active Controlled Study Evaluating the Efficacy of Vortioxetine Versus Desvenlafaxine in Adult Patients Suffering From Major Depressive Disorder With Partial Response to SSRI Treatment [NCT04448431]	Phase 4	605 participants (Actual)	Interventional	2020-06-18	Completed
Efficacy Of Switching From SSRI to Desvenlafaxine on Cognitive Function In Patients With an Acute Episode of Major Depression [NCT03432221]		36 participants (Anticipated)	Observational	2018-04-03	Recruiting
A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness. [NCT01803711]	Phase 2/Phase 3	6 participants (Actual)	Interventional	2013-02-28	Terminated(stopped due to Lack of recruitment and no resources)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00369343 (13) [back to overview]	Percentage of Patients Achieving Remission
NCT00369343 (13) [back to overview]	Percentage of Patients Achieving Response to Treatment
NCT00369343 (13) [back to overview]	Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Open Label Baseline to 6 Months
NCT00369343 (13) [back to overview]	Percentage of Patients Achieving Remission
NCT00369343 (13) [back to overview]	Percentage of Patients With Each Clinical Global Impression Improvement (CGI-I) Score
NCT00369343 (13) [back to overview]	Discontinuation-Emergent Signs and Symptoms (DESS) Total Score
NCT00369343 (13) [back to overview]	Clinical Global Impression Improvement (CGI-I) Score
NCT00369343 (13) [back to overview]	Percentage of Patients Achieving a Response to Treatment
NCT00369343 (13) [back to overview]	Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Baseline to Week 8
NCT00369343 (13) [back to overview]	Change in Dimension Health State EuroQol (EQ-5D) Score From Baseline to Week 8
NCT00369343 (13) [back to overview]	Change in Dimension Health State EuroQol (EQ-5D) Score From Open Label Baseline to 6 Months
NCT00369343 (13) [back to overview]	Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Open Label Baseline to 6 Months
NCT00369343 (13) [back to overview]	Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8.
NCT00384033 (9) [back to overview]	Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) Score at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in HAM-D17 Total Score at Week 8 or Final On-therapy (FOT) Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in Mean CGI-S Score at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in Covi Anxiety Scale at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in HAM-D6 Total Score at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in the HAM-D Energy Subscale Score at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in the Lassitude Item of the MADRS Scale at Week 8 or FOT Evaluation
NCT00384033 (9) [back to overview]	Change From Baseline in Visual Analog Scale-Pain Intensity (VAS-PI) Overall and Subcomponent Score at Week 8 or FOT Evaluation
NCT00401245 (15) [back to overview]	Percentage of Participants Discontinuing Treatment Due to AEs in First 2 Weeks of Treatment
NCT00401245 (15) [back to overview]	DESS Total Score at 1 Week After the End of Tapering
NCT00401245 (15) [back to overview]	DESS Total Score at End of Second Week of Tapering
NCT00401245 (15) [back to overview]	Discontinuation Emergent Signs and Symptoms (DESS) Total Score at the End of First Week of Tapering
NCT00401245 (15) [back to overview]	Mean Age of the Participants in Tapering Phase
NCT00401245 (15) [back to overview]	Number of Participants With Nausea During the First 2 Weeks of Treatment
NCT00401245 (15) [back to overview]	Number of Participants With Other Spontaneously Reported Adverse Events (AEs) in First 2 Weeks of Treatment
NCT00401245 (15) [back to overview]	Number of Participants Showing Satisfaction With Tolerability at the End of Tapering
NCT00401245 (15) [back to overview]	Number of Participants With Each DESS One Week After End of Tapering
NCT00401245 (15) [back to overview]	Number of Participants With Each DESS at the End of Second Week of Tapering
NCT00401245 (15) [back to overview]	Number of Participants With Each DESS at the End of First Week of Tapering
NCT00401245 (15) [back to overview]	Number of Participants Showing Satisfaction With Tolerability During the First Two Weeks of Treatment
NCT00401245 (15) [back to overview]	Menopause Symptoms-treatment Satisfaction Questionnaire (MS-TSQ) Score
NCT00401245 (15) [back to overview]	Gender of the Participants in Tapering Phase
NCT00401245 (15) [back to overview]	Change From Baseline in Menopause-specific Quality of Life Questionnaire (MenQOL) Score at Week 4, Week 8, Week 12 and Week 16
NCT00406640 (13) [back to overview]	Clinical Global Impression Improvement (CGI-I) Score at 8 Weeks
NCT00406640 (13) [back to overview]	Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8
NCT00406640 (13) [back to overview]	Change in Dimension Health State EuroQol (EQ-5D) Score From Baseline to Week 8
NCT00406640 (13) [back to overview]	Change in Clinical Global Impression Severity (CGI-S) Score From Baseline to Week
NCT00406640 (13) [back to overview]	Percentage of Patients Achieving Response to Treatment at Final On-therapy Evaluation (Acute Phase)
NCT00406640 (13) [back to overview]	Percentage of Non-Responders Achieving Remission at Final Evaluation of 6-month Open-Label Extension Phase
NCT00406640 (13) [back to overview]	Change in Hamilton Psychiatric Rating Scale for Anxiety From Baseline to Week 8 (HAM-A) Score
NCT00406640 (13) [back to overview]	Percentage of Non-Responders Achieving Response at Final Evaluation of 6-month Open-Label (OL)Extension Phase
NCT00406640 (13) [back to overview]	Percentage of Patients Achieving Remission at Final On-therapy Evaluation (Acute Phase)
NCT00406640 (13) [back to overview]	Percentage of Responders Achieving Remission at Final On-therapy Evaluation (Double Blind Continuation Phase)
NCT00406640 (13) [back to overview]	Percentage of Responders Improving Response to Remission During 6-month Double Blind Continuation Phase
NCT00406640 (13) [back to overview]	Percentage of Responders Maintaining Response to Treatment at Final On-therapy Evaluation (Double Blind Continuation Phase)
NCT00406640 (13) [back to overview]	Discontinuation-Emergent Signs and Symptoms (DESS) Total Score
NCT00619619 (9) [back to overview]	Area Under the Curve From Time Zero to Infinity (AUC0-∞)
NCT00619619 (9) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT00619619 (9) [back to overview]	Plasma Decay Half-Life (t1/2)
NCT00619619 (9) [back to overview]	Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit
NCT00619619 (9) [back to overview]	Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs)
NCT00619619 (9) [back to overview]	Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit
NCT00619619 (9) [back to overview]	Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score
NCT00619619 (9) [back to overview]	Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score
NCT00619619 (9) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT00669110 (16) [back to overview]	Percentage of Participants With a Categorical Clinical Global Impressions Scales - Severity (CGI-S) Score
NCT00669110 (16) [back to overview]	Percentage of Participants With a Categorical Clinical Global Impressions Scales - Improvement (CGI-I) Score
NCT00669110 (16) [back to overview]	Number of Participants With Vital Sign Results of Potential Clinical Importance (PCI): Weight
NCT00669110 (16) [back to overview]	Number of Participants With Vital Sign Results of Potential Clinical Importance (PCI): Pulse Rate
NCT00669110 (16) [back to overview]	Number of Participants With Vital Sign Results of Potential Clinical Importance (PCI): Blood Pressure (BP)
NCT00669110 (16) [back to overview]	Number of Participants With Laboratory Test Results of Potential Clinical Importance (PCI)
NCT00669110 (16) [back to overview]	Change From Baseline (Bsl) in Hamilton Rating Scale for Depression 17-item (HAM-D17) Total Score
NCT00669110 (16) [back to overview]	Number of Participants With Electrocardiogram (ECG) Results of Potential Clinical Importance (PCI)
NCT00669110 (16) [back to overview]	Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs)
NCT00669110 (16) [back to overview]	Change From Baseline in Number of Participants for Tanner Assessment at Week 26: Males
NCT00669110 (16) [back to overview]	Change From Baseline in Number of Participants for Tanner Assessment at Week 26: Females
NCT00669110 (16) [back to overview]	Change From Baseline (Bsl) in Children's Depression Rating Scale - Revised (CDRS-R) Total Score at Final On-therapy Visit
NCT00669110 (16) [back to overview]	Number of Participants With Electrocardiogram (ECG) Results of Potential Clinical Importance (PCI): Heart Rate (Low)
NCT00669110 (16) [back to overview]	Number of Participants for Columbia Suicide-Severity Rating Scale (C-SSRS) According to the Columbia Classification Algorithm of Suicide Assessment (C-CASA) Categories
NCT00669110 (16) [back to overview]	Percentage of Participants With Remission (Total Score ≤28) Based on Children's Depression Rating Scale - Revised (CDRS-R)
NCT00669110 (16) [back to overview]	Percentage of Participants With a Response of Much Improved or Very Much Improved Based on the Clinical Global Impressions Scales - Improvement (CGI-I) Score
NCT00683800 (30) [back to overview]	Change From Baseline in the Average Daily Severity of Hot Flushes at Week 4
NCT00683800 (30) [back to overview]	Median Time to the First Day of 3 Consecutive Days of at Least 50% Reduction in Hot Flushes
NCT00683800 (30) [back to overview]	Number of Participants With a Minimal Clinically Meaningful Decrease in the Average Daily Number of Hot Flushes
NCT00683800 (30) [back to overview]	Number of Participants With Adjudicated Cerebrovascular Events - Probable TIA
NCT00683800 (30) [back to overview]	Number of Participants With Hepatic Events
NCT00683800 (30) [back to overview]	Number of Participants With Ischemic Heart Disease
NCT00683800 (30) [back to overview]	Change From Baseline in Adjusted Means in the Hot Flush Severity Score at Month 6 and Month 12
NCT00683800 (30) [back to overview]	Change From Baseline in Adjusted Means in the Number of Moderate and Severe Hot Flushes at Month 6 and Month 12
NCT00683800 (30) [back to overview]	Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Month 12
NCT00683800 (30) [back to overview]	Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Month 6
NCT00683800 (30) [back to overview]	Change From Baseline in the Total Greene Climacteric Scale (GCS) Score and GCS Subscores at Week 12
NCT00683800 (30) [back to overview]	Number of Participants With Adjudicated Cerebrovascular Events - Any Stroke
NCT00683800 (30) [back to overview]	Number of Participants With All Adjudicated Ischemic Cardiovascular (CV) Events
NCT00683800 (30) [back to overview]	Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Moderate and Severe Hot Flushes
NCT00683800 (30) [back to overview]	Percentage of Participants With at Least 75% Reduction From Baseline in the Number of Moderate and Severe Hot Flushes
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores Based on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Month 12
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores Based on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Month 12
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Month 6
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for Main Study Efficacy Population at Week 12
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Month 6
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores on Patient Global Impression Change (PGI-C) for MITT Population of Efficacy Substudy at Week 12
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Month 12
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Month 6
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for Main Study Efficacy Population at Week 12
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Month 12
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Month 6
NCT00683800 (30) [back to overview]	Percentage of Participants With Categorical Scores on Patient Global Impression Symptom Rating (PGI-R) for MITT Population of Efficacy Substudy at Week 12
NCT00683800 (30) [back to overview]	Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 12
NCT00683800 (30) [back to overview]	Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4
NCT00683800 (30) [back to overview]	Change From Baseline in the Average Daily Severity of Hot Flushes at Week 12
NCT00696787 (2) [back to overview]	Change From Baseline on the Numeric Rating Scale (NRS) in the Treatment of Pain Associated With Fibromyalgia in Adult Female Outpatients
NCT00696787 (2) [back to overview]	Change From Baseline on the Numeric Rating Scale (NRS)
NCT00727064 (6) [back to overview]	Area Under the Concentration-time Curve (AUC) of Desvenlafaxine After Single Dose of DVS SR by Metabolizer Status
NCT00727064 (6) [back to overview]	Area Under the Concentration-time Curve (AUC) of Desvenlafaxine After Single Dose of VEN ER by Metabolizer Status
NCT00727064 (6) [back to overview]	Area Under the Concentration-time Curve (AUC) of Venlafaxine After Single Dose of VEN ER by Metabolizer Status
NCT00727064 (6) [back to overview]	Maximum Concentration (Cmax) of Desvenlafaxine After Single Dose of Desvenlafaxine Succinate Sustained-Release (DVS SR) by Metabolizer Status
NCT00727064 (6) [back to overview]	Maximum Concentration (Cmax) of Desvenlafaxine After Single Dose of VEN ER by Metabolizer Status
NCT00727064 (6) [back to overview]	Maximum Concentration (Cmax) of Venlafaxine After Single Dose of Venlafaxine Extended-release (VEN ER) by Metabolizer Status
NCT00797966 (14) [back to overview]	Percentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).
NCT00797966 (14) [back to overview]	Percentage of Participants With MADRS Response From End of Phase A (Week 8 Visit).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).
NCT00797966 (14) [back to overview]	Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
NCT00797966 (14) [back to overview]	Change From End of Phase A (Week 8 Visit) in Mean CGI-S Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
NCT00797966 (14) [back to overview]	Clinical Global Impression-Improvement Scale (CGI-I) Score at Each Study Week Visit in Phase B.
NCT00797966 (14) [back to overview]	Percentage of Participants With CGI-I Response From End of Phase A (Week 8 Visit).
NCT00798707 (14) [back to overview]	Discontinuation-Emergent Signs and Symptoms (DESS) Total Score
NCT00798707 (14) [back to overview]	Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Number of Participants With Categorical Scores on the C-SSRS at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Change From Baseline in SDS at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Percentage of Participants With Sexual Dysfunction at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Number of Participants With a Response on the MADRS Score at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Number of Participants With a Response on the CGI-I Score at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Change From Baseline in WHO-5 Total Score at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Number of Participants in Remission Based on the HAM-D17 at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Change From Baseline in MADRS Total Score at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Change From Baseline in HAM-D6 Total Score at FOT Evaluation (Week 8 or ET)
NCT00798707 (14) [back to overview]	Change From Baseline in HAM-D17 Total Score at the Final On-therapy (FOT)Evaluation (Week 8 or ET)
NCT00824291 (8) [back to overview]	Change From Baseline on Worry Anxiety Tension Scale (WATS) at Week 12
NCT00824291 (8) [back to overview]	Change From Baseline on Work and Activities Item of HAM-D17 at Week 12
NCT00824291 (8) [back to overview]	Change From Baseline on Stress and Social Support Scales at Week 12
NCT00824291 (8) [back to overview]	Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 12
NCT00824291 (8) [back to overview]	Change From Baseline in Hamilton Depression Scale (HAM-D) at Week 12
NCT00824291 (8) [back to overview]	Change From Baseline in Adjusted Mean on Montgomery-Asberg Depression Rating Scale (MADRS) at Week 12
NCT00824291 (8) [back to overview]	Clinical Global Impressions Scale - Severity of Illness (CGI-S) at Week 12
NCT00824291 (8) [back to overview]	Clinical Global Impression Scale - Improvement (CGI- I) Score at Week 12
NCT00831415 (4) [back to overview]	Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score
NCT00831415 (4) [back to overview]	Change From Baseline in Clinical Global Impression-Severity of Illness [CGI-S] Score
NCT00831415 (4) [back to overview]	Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
NCT00831415 (4) [back to overview]	Number of Participants With Categorical Scores on Clinical Global Impression-Improvement (CGI-I)
NCT00863798 (14) [back to overview]	Change From Baseline in HAM-D17 Total Score at Final On-therapy (FOT) Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Number of Participants With Categorical Scores on the C-SSRS at FOT Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) at FOT Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Discontinuation-Emergent Signs and Symptoms (DESS)
NCT00863798 (14) [back to overview]	Percentage of Participants With Sexual Dysfunction at FOT Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Number of Participants With a Response on the MADRS Score at FOT Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Number of Participants With a Response on the HAM-D17 at FOT Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Number of Participants With a Response on the CGI-I Score at FOT Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Number of Participants in Remission Based on the HAM-D17 at FOT Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Change From Baseline in WHO-5 Total Score at FOT Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Change From Baseline in Mean CGI-S Score at FOT Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Change From Baseline in MADRS Total Score at FOT Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Change From Baseline in HAM-D6 Total Score at FOT Evaluation (Week 8 or ET)
NCT00863798 (14) [back to overview]	Change From Baseline in SDS at FOT Evaluation (Week 8 or ET)
NCT00887224 (8) [back to overview]	Number of Participants With Remission Based on Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score at Double-blind Phase Week 26
NCT00887224 (8) [back to overview]	Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185
NCT00887224 (8) [back to overview]	Change From Baseline in Clinical Global Impression-Severity of Illness [CGI-S] Score in the Double-blind Phase
NCT00887224 (8) [back to overview]	Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score in the Double-blind Phase
NCT00887224 (8) [back to overview]	Change From Baseline in Hamilton Psychiatric Scale for Depression-6 Item (HAM-D6) Score in the Double-blind Phase
NCT00887224 (8) [back to overview]	Change From Baseline of Double-blind Phase in World Health Organization (Five-Item) Well-Being Index
NCT00887224 (8) [back to overview]	Number of Participants Per Categorical Score for Change From Baseline on Clinical Global Impression-Improvement (CGI-I) Scale
NCT00887224 (8) [back to overview]	Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Score in the Double-blind Phase
NCT00952653 (10) [back to overview]	Midazolam Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) Following Midazolam Alone and When Coadministered With DVS SR
NCT00952653 (10) [back to overview]	Midazolam Maximum Observed Plasma Concentration (Cmax) Following Midazolam Alone and When Coadministered With DVS SR
NCT00952653 (10) [back to overview]	Midazolam Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Midazolam Alone and When Coadministered With DVS SR
NCT00952653 (10) [back to overview]	1-Hydroxy-Midazolam (Analyte) Time to Cmax (Tmax) Following Midazolam Alone and When Coadministered With DVS SR
NCT00952653 (10) [back to overview]	1-Hydroxy-Midazolam (Analyte) Terminal Half-life (t 1/2) Following Midazolam Alone and When Coadministered With DVS SR
NCT00952653 (10) [back to overview]	1-Hydroxy-Midazolam (Analyte) Maximum Observed Plasma Concentration (Cmax) Following Midazolam Alone and When Coadministered With DVS SR
NCT00952653 (10) [back to overview]	1-Hydroxy-Midazolam (Analyte) Area Under the Plasma Concentration-time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) Following Midazolam Alone and When Coadministered With DVS SR
NCT00952653 (10) [back to overview]	1-Hydroxy-Midazolam (Analyte) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Midazolam Alone and When Coadministered With DVS SR
NCT00952653 (10) [back to overview]	Midazolam Terminal Half-life (t 1/2) Following Midazolam Alone and When Coadministered With DVS SR
NCT00952653 (10) [back to overview]	Midazolam Time to Cmax (Tmax) Following Midazolam Alone and When Coadministered With DVS SR
NCT01056289 (3) [back to overview]	Percentage of Participants Who Were Unable to Successfully Complete Tapering of the Study Drug Because of the Number and/or Severity of Their Discontinuation Symptoms
NCT01056289 (3) [back to overview]	Percentage of Participants With Taper Adverse Events (AEs) in the Double-blind Phase
NCT01056289 (3) [back to overview]	Total Discontinuation - Emergent Signs and Symptoms (DESS) Score Over the First 2 Weeks of the Double-blind Phase
NCT01121484 (6) [back to overview]	Number of Participants With Categorical Scores on Clinical Global Impression - Improvement (CGI-I)
NCT01121484 (6) [back to overview]	Change From Baseline in Clinical Global Impression - Severity (CGI-S) at Week 8
NCT01121484 (6) [back to overview]	Change From Baseline in Visual Analogue Scale for Pain (VAS-pain) at Week 8
NCT01121484 (6) [back to overview]	Change From Baseline in Quick Inventory of Depressive Symptoms, 16 Question Self-report (QIDS-SR)
NCT01121484 (6) [back to overview]	Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) - Total Score at Week 8
NCT01121484 (6) [back to overview]	Change From Baseline in Hamilton Depression Scale (HAM-D17) at Week 8
NCT01188668 (12) [back to overview]	Dehydro-aripiprazole (Metabolite) Terminal Half-life (t 1/2) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Plasma Dehydro-aripiprazole (Metabolite) Concentration Versus Time Summary: Aripiprazole 5mg, DVS SR 100 mg, Aripiprazole 5 mg
NCT01188668 (12) [back to overview]	Aripiprazole Apparent Volume of Distribution (Vz/F) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Plasma Aripiprazole Concentration Versus Time Summary: Aripiprazole 5mg, DVS SR 100 mg + Aripiprazole 5 mg
NCT01188668 (12) [back to overview]	Aripiprazole Maximum Observed Plasma Concentration (Cmax) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Aripiprazole Apparent Clearance (CL/F) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Aripiprazole Time for Cmax (Tmax) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Aripiprazole Terminal Half-life (t 1/2) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Dehydro-aripiprazole (Metabolite) Time for Cmax (Tmax) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Dehydro-aripiprazole (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Dehydro-aripiprazole (Metabolite) Maximum Observed Plasma Concentration (Cmax) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01188668 (12) [back to overview]	Aripiprazole Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Aripiprazole Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Tamoxifen Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Tamoxifen Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Tamoxifen Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Tamoxifen Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Plasma 4-hydroxy-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Plasma Endoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Plasma N-desmethyl-tamoxifen (Metabolite) Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Plasma Tamoxifen Concentration Versus Time Summary: Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	4-hydroxy-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	4-hydroxy-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	4-hydroxy-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	4-hydroxy-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Endoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Endoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Endoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Endoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Endoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	N-desmethyl-tamoxifen (Metabolite) Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	N-desmethyl-tamoxifen (Metabolite) Maximum Observed Concentration (Cmax) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	N-desmethyl-tamoxifen (Metabolite) Terminal Half-life (t 1/2) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	N-desmethyl-tamoxifen (Metabolite) Time for Cmax (Tmax) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Tamoxifen Apparent Clearance (CL/F) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01189500 (22) [back to overview]	Tamoxifen Apparent Volume of Distribution (Vz/F) Following Tamoxifen Alone and When Coadministered With DVS SR
NCT01190514 (6) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax)
NCT01190514 (6) [back to overview]	Terminal Elimination Half-life (t 1/2)
NCT01190514 (6) [back to overview]	Maximum Plasma Concentration (Cmax)
NCT01190514 (6) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 to 48 Hours (AUC48)
NCT01190514 (6) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Time of the Last Quantifiable Concentration (AUClast)
NCT01190514 (6) [back to overview]	Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf)
NCT01316302 (3) [back to overview]	Change in the Liebowitz Social Anxiety Scale (LSAS) Total Score
NCT01316302 (3) [back to overview]	Clinical Global Impression of Improvement Scale (CGI-I)
NCT01316302 (3) [back to overview]	Patient Global Impression of Change
NCT01353963 (7) [back to overview]	Change From Baseline in Weight at Week 8.
NCT01353963 (7) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs), or Discontinuation Due to Adverse Events (AEs)
NCT01353963 (7) [back to overview]	Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Week 8.
NCT01353963 (7) [back to overview]	Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Week 4.
NCT01353963 (7) [back to overview]	Change From Baseline in Weight at Week 4.
NCT01353963 (7) [back to overview]	Change From Baseline in Heart Rate at Week 8.
NCT01353963 (7) [back to overview]	Change From Baseline in Heart Rate at Week 4.
NCT01371734 (4) [back to overview]	Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Weeks 1, 2, 3, 4, 6, and 8
NCT01371734 (4) [back to overview]	Percentage of Participants With a CGI-I Response Defined as a Score of 'Very Much Improved' or 'Much Improved'
NCT01371734 (4) [back to overview]	Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score (n=102, 104, 106)
NCT01371734 (4) [back to overview]	Change From Baseline to Week 8 in the Clinical Global Impression of Severity (CGI-S) Score (n=102, 105, 106)
NCT01372150 (4) [back to overview]	Percentage of Participants With a CGI-I Response Defined as a Score of 'Very Much Improved' or 'Much Improved'
NCT01372150 (4) [back to overview]	Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Weeks 1, 2, 3, 4, 6, and 8
NCT01372150 (4) [back to overview]	Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score
NCT01372150 (4) [back to overview]	Change From Baseline to Week 8 in the Clinical Global Impression of Severity (CGI-S) Score
NCT01432457 (8) [back to overview]	Change From Baseline on the Arizona Sexual Experiences (ASEX) Scale Total Score
NCT01432457 (8) [back to overview]	Change From Baseline on the Clinical Global Impression-Severity (CGI-S) Score
NCT01432457 (8) [back to overview]	Change From Baseline on the Clinical Global Impression-Severity Score (CGI-S)
NCT01432457 (8) [back to overview]	Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17) at Week 8
NCT01432457 (8) [back to overview]	Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17) at Week 8
NCT01432457 (8) [back to overview]	Hamilton Rating Scale for Depression, 17-item (HAM-D17) Remission Rate
NCT01432457 (8) [back to overview]	Hamilton Rating Scale for Depression, 17-item (HAM-D17) Response Rate
NCT01432457 (8) [back to overview]	Change From Baseline on the Clinical Global Impression Scale-Improvement (CGI-I)
NCT01537068 (3) [back to overview]	Response Rate
NCT01537068 (3) [back to overview]	Hamilton Rating Scale for Depression (HDRS24)
NCT01537068 (3) [back to overview]	Hamilton Rating Scale for Depression (HDRS24)
NCT01916824 (1) [back to overview]	Money Earned
NCT04476030 (16) [back to overview]	Change From Baseline in Depressive Symptoms at Day 15, as Assessed by PHQ-9
NCT04476030 (16) [back to overview]	Change From Baseline in CGI-S Score at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in HAM-A Total Score at Day 15
NCT04476030 (16) [back to overview]	Percentage of Participants With HAMD-17 Remission at Day 15 and Day 42
NCT04476030 (16) [back to overview]	Percentage of Participants With CGI-I Response, at Day 3 and Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score at Days 15 and 42
NCT04476030 (16) [back to overview]	Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT04476030 (16) [back to overview]	Percentage of Participants With TEAEs, Graded by Severity
NCT04476030 (16) [back to overview]	Percentage of Participants With HAMD-17 Response at Day 15 and Day 42
NCT04476030 (16) [back to overview]	Time to First HAMD-17 Response
NCT04476030 (16) [back to overview]	Percentage of Participants With MADRS Response at Day 15
NCT04476030 (16) [back to overview]	Percentage of Participants With MADRS Remission at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score at Day 3
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score Around End of Blinded Treatment
NCT04476030 (16) [back to overview]	Change From Baseline in MADRS Total Score at Day 15
NCT04476030 (16) [back to overview]	Change From Baseline in the HAMD-17 Total Score Over the Double-Blind Treatment Period

Percentage of Patients Achieving Remission

Remission is defined as a Hamilton Psychiatric Rating Scale for Depression (HAM-D17) score of ≤ 7. HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on a 0 to 2-4 scale (0=none/absent and 4=most severe) with a maximum total score of 50. (NCT00369343)
Timeframe: 8 weeks

Intervention	percentage of patients (Number)
Desvenlafaxine Succinate Sustained-Release (DVS SR)	38.2
Placebo	22.4

Intervention	percentage of patients (Number)
Desvenlafaxine Succinate Sustained-Release (DVS SR)	58.6
Placebo	31.6

Intervention	percentage of patients (Number)
	1 (very much improved)	2 (much improved)	3 (minimally improved)	4 (no change)	5 (minimally worse)	6 (much worse)	7 (very much worse)
Desvenlafaxine Succinate Sustained-Release (DVS SR)	42.5	25.3	16.7	13.4	1.1	0.5	0.5
Placebo	22.7	18.6	17.5	32.0	7.2	2.1	0.0

Intervention	units on scale (Mean)
	End of 8 week DB / OL phase or early termination	Taper week 1	Taper week 2	Post-taper
0 mg	4.00	2.00	1.40	0.60
100 mg	2.07	3.32	5.29	1.41
200 mg	1.27	2.47	3.76	2.46

Intervention	units on scale (Mean)
Desvenlafaxine Succinate Sustained-Release (DVS SR)	-8.62
Placebo	-5.89

Intervention	units on scale (Mean)
Desvenlafaxine Succinate Sustained-Release (DVS SR)	0.18
Placebo	0.06

Intervention	units on scale (Mean)
Desvenlafaxine Succinate Sustained-Release (DVS SR)	-12.64
Placebo	-8.33

Intervention	Participants (Number)
	1 = Very much improved	2 = Much improved	3 = Minimally improved	4 = No change	5 = Minimally worse
Duloxetine 60 mg	45	35	37	37	3
DVS SR 100 mg	45	37	28	37	2
DVS SR 50 mg	27	38	47	34	2
Placebo	31	32	35	57	5

Intervention	Units on a Scale (Mean)
Placebo	-8.68
DVS SR 50 mg	-9.75
DVS SR 100 mg	-10.5
Duloxetine 60 mg	-10.3

Intervention	Units on a Scale (Mean)
Placebo	-1.10
DVS SR 50 mg	-1.25
DVS SR 100 mg	-1.44
Duloxetine 60 mg	-1.41

Intervention	Units on a Scale (Mean)
	Baseline	Change at Week 8 or FOT
Duloxetine 60 mg	6.30	-1.47
DVS SR 100 mg	6.30	-1.35
DVS SR 50 mg	6.30	-1.15
Placebo	6.50	-1.02

Intervention	mm (Mean)
	Overall pain (Baseline)	Stomach pain (Baseline)	Back pain (Baseline)	Chest pain (Baseline)	Arms, legs or joint pain (Baseline)	Overall pain (Change at Week 8 or FOT)	Stomach pain (Change at Week 8 or FOT)	Back pain (Change at Week 8 or FOT)	Chest pain (Change at Week 8 or FOT)	Arms, legs or joint pain (Change at Week 8 or FOT)
Duloxetine 60 mg	26.10	14.00	25.50	6.60	22.40	-8.84	-4.38	-9.33	-1.67	-8.35
DVS SR 100 mg	25.90	17.00	28.30	10.40	28.70	-10.30	-6.42	-12.80	-3.90	-11.90
DVS SR 50 mg	30.80	19.40	32.90	10.90	29.10	-9.08	-4.98	-10.70	-3.34	-8.98
Placebo	26.30	16.70	25.90	9.40	25.80	-5.61	-1.86	-7.04	-1.95	-6.99

Intervention	Years (Mean)
DVS 50 mg QOD	53.72
DVS 50/25 mg	54.56
DVS 50 mg/Placebo	54.20
Placebo	54.14

Intervention	Percentage of participants (Number)
DVS 25 mg, Then 100 mg	4.0
DVS 25/50 mg, Then 100 mg	9.1
DVS 50 mg, Then 100 mg	6.5
DVS 100 mg, Then 100 mg	14.8

Intervention	Units on a scale (Mean)
DVS 50 mg QOD	3.22
DVS 50/25 mg	4.11
DVS 50 mg/Placebo	1.70
Placebo	1.78

Intervention	Units on a scale (Mean)
DVS 50 mg QOD	1.19
DVS 50/25 mg	2.44
DVS 50 mg/Placebo	4.46
Placebo	2.44

Intervention	Units on a scale (Mean)
DVS 50 mg QOD	2.26
DVS 50/25 mg	2.28
DVS 50 mg/Placebo	1.84
Placebo	7.07

Intervention	Participants (Number)
	Extremely dissatisfied	Dissatisfied	Neutral	Satisfied	Extremely satisfied
DVS 50 mg QOD	7	10	10	16	10
DVS 50 mg/Placebo	3	3	5	19	10
DVS 50/25 mg	5	7	5	23	12
Placebo	6	5	7	19	18

Intervention	Participants (Number)
	Agitation	Blurred vision	Bouts of crying or tearfulness	Burning, numbness, tingling sensations	Chills	Confusion or trouble concentrating	Diarrhea	Dizziness, lightheadedness, sensation of spinning	Elevated mood, feeling high	Fatigue, tiredness	Feeling unreal or detached	Fever	Forgetfulness or problems with memory	Headaches	Increased dreaming or nightmares	Increased saliva in mouth	Irritability	Mood swings	Muscle aches or pains	Muscle cramps, spasms, or twitching	Muscle tension or stiffness	Nausea	Nervousness or anxiety	Nose running	Problems with speech or speaking clearly	Restless feeling in legs	Ringing or noises in the ears	Shaking, trembling	Shortness of breath, gasping for air	Sore eyes	Stomach bloating	Stomach cramps	Sudden outbursts of anger	Sudden panic or anxiety attacks	Sudden worsening of mood	Sweating more than usual	Trouble sleeping, insomnia	Uncontrolled mouth/tongue movements	Unsteady gait or incoordination	Unusual sensitivity to sound	Unusual tastes or smells	Unusual visual sensations	Vomiting
DVS 50 mg QOD	6	2	7	2	3	6	3	13	1	9	6	2	5	4	7	0	11	4	5	5	5	5	9	1	0	1	3	3	1	3	3	2	4	1	7	21	12	0	4	1	1	0	1
DVS 50 mg/Placebo	6	0	2	0	1	4	1	2	0	2	1	0	2	3	0	1	7	6	5	1	3	0	5	3	0	3	0	0	1	1	1	0	3	2	5	4	5	0	0	0	0	0	0
DVS 50/25 mg	4	0	7	9	3	7	3	17	2	10	5	0	3	11	10	1	9	5	8	5	9	5	10	2	2	6	8	3	1	4	4	3	3	5	4	19	13	1	5	2	3	3	0
Placebo	5	1	3	2	3	2	1	0	0	8	3	0	3	5	3	1	6	4	3	1	2	1	3	1	0	1	0	1	0	2	4	2	5	2	5	12	7	0	1	1	0	1	0

Intervention	Participants (Number)
	Week 1: Extremely dissatisfied (n=124,119,120,111)	Week 1: Dissatisfied (n=124,119,120,111)	Week 1: Neutral (n=124,119,120,111)	Week 1: Satisfied (n=124,119,120,111)	Week 1: Extremely satisfied (n=124,119,120,111)	Week 2: Extremely dissatisfied (n=115,105,113,94)	Week 2: Dissatisfied (n=115,105,113,94)	Week 2: Neutral (n=115,105,113,94)	Week 2: Satisfied (n=115,105,113,94)	Week 2: Extremely satisfied (n=115,105,113,94)
DVS 100 mg, Then 100 mg	4	16	19	39	33	0	1	15	40	38
DVS 25 mg, Then 100 mg	2	1	20	47	54	2	3	17	43	50
DVS 25/50 mg, Then 100 mg	3	6	13	48	49	0	4	17	35	49
DVS 50 mg, Then 100 mg	1	8	28	43	40	0	8	18	41	46

Intervention	Units on a scale (Mean)
	Ability to control hot flushes during the day	Ability to control hot flushes during the night	Effect on quality of sleep	Effect on mood or emotions	Effect on interest in sex	Effect on ability to concentrate	Tolerability to side effects	Overall satisfaction
DVS 100 mg	2.64	2.71	2.59	3.02	2.37	2.67	3.04	2.81

Intervention	Participants (Number)
	Female	Male
DVS 50 mg QOD	101	0
DVS 50 mg/Placebo	87	0
DVS 50/25 mg	94	0
Placebo	102	0

Intervention	Units on a scale (Mean)
	Baseline	Week 4 (n=385)	Week 8 (n=364)	Week 12 (n=354)	Week 16 (n=277)
DVS 100 mg	4.46	2.99	2.85	2.76	2.67

desvenlafaxine succinate

Description

Cross-References

Synonyms (36)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (322)

Study Types

Clinical Trials (74)

Trial Overview

Trial Outcomes

Percentage of Patients Achieving Remission

Percentage of Patients Achieving Response to Treatment

Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Open Label Baseline to 6 Months

Percentage of Patients Achieving Remission

Percentage of Patients With Each Clinical Global Impression Improvement (CGI-I) Score

Discontinuation-Emergent Signs and Symptoms (DESS) Total Score

Clinical Global Impression Improvement (CGI-I) Score

Percentage of Patients Achieving a Response to Treatment

Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Baseline to Week 8

Change in Dimension Health State EuroQol (EQ-5D) Score From Baseline to Week 8

Change in Dimension Health State EuroQol (EQ-5D) Score From Open Label Baseline to 6 Months

Change in Hamilton Psychiatric Rating Scale for Anxiety (HAM-A) Score From Open Label Baseline to 6 Months

Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8.

Number of Participants With Categorical Scores on CGI-Improvement (CGI-I) Score at Week 8 or FOT Evaluation

Change From Baseline in HAM-D17 Total Score at Week 8 or Final On-therapy (FOT) Evaluation

Change From Baseline in Mean CGI-S Score at Week 8 or FOT Evaluation

Change From Baseline in Covi Anxiety Scale at Week 8 or FOT Evaluation

Change From Baseline in HAM-D6 Total Score at Week 8 or FOT Evaluation

Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Week 8 or FOT Evaluation

Change From Baseline in the HAM-D Energy Subscale Score at Week 8 or FOT Evaluation

Change From Baseline in the Lassitude Item of the MADRS Scale at Week 8 or FOT Evaluation

Change From Baseline in Visual Analog Scale-Pain Intensity (VAS-PI) Overall and Subcomponent Score at Week 8 or FOT Evaluation

Percentage of Participants Discontinuing Treatment Due to AEs in First 2 Weeks of Treatment

DESS Total Score at 1 Week After the End of Tapering

DESS Total Score at End of Second Week of Tapering

Discontinuation Emergent Signs and Symptoms (DESS) Total Score at the End of First Week of Tapering

Mean Age of the Participants in Tapering Phase

Number of Participants With Nausea During the First 2 Weeks of Treatment

Number of Participants With Other Spontaneously Reported Adverse Events (AEs) in First 2 Weeks of Treatment

Number of Participants Showing Satisfaction With Tolerability at the End of Tapering

Number of Participants With Each DESS One Week After End of Tapering

Number of Participants With Each DESS at the End of Second Week of Tapering

Number of Participants With Each DESS at the End of First Week of Tapering

Number of Participants Showing Satisfaction With Tolerability During the First Two Weeks of Treatment

Menopause Symptoms-treatment Satisfaction Questionnaire (MS-TSQ) Score

Gender of the Participants in Tapering Phase

Change From Baseline in Menopause-specific Quality of Life Questionnaire (MenQOL) Score at Week 4, Week 8, Week 12 and Week 16

Clinical Global Impression Improvement (CGI-I) Score at 8 Weeks

Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8

Change in Dimension Health State EuroQol (EQ-5D) Score From Baseline to Week 8

Change in Clinical Global Impression Severity (CGI-S) Score From Baseline to Week

Percentage of Patients Achieving Response to Treatment at Final On-therapy Evaluation (Acute Phase)

Percentage of Non-Responders Achieving Remission at Final Evaluation of 6-month Open-Label Extension Phase

Change in Hamilton Psychiatric Rating Scale for Anxiety From Baseline to Week 8 (HAM-A) Score

Percentage of Non-Responders Achieving Response at Final Evaluation of 6-month Open-Label (OL)Extension Phase

Percentage of Patients Achieving Remission at Final On-therapy Evaluation (Acute Phase)

Percentage of Responders Achieving Remission at Final On-therapy Evaluation (Double Blind Continuation Phase)

Percentage of Responders Improving Response to Remission During 6-month Double Blind Continuation Phase

Percentage of Responders Maintaining Response to Treatment at Final On-therapy Evaluation (Double Blind Continuation Phase)

Discontinuation-Emergent Signs and Symptoms (DESS) Total Score

Area Under the Curve From Time Zero to Infinity (AUC0-∞)

Time to Reach Maximum Observed Plasma Concentration (Tmax)

Plasma Decay Half-Life (t1/2)

Percentage of Participants With a Categorical Clinical Global Impressions Scale-Severity (CGI-S) Score at Every Visit

Number of Participants With Adverse Events AEs) and Serious Adverse Events (SAEs)

Percentage of Participants With a Categorical Clinical Global Impressions Scale-Improvement(CGI-I) Score at Every Visit

Change From Baseline in Hamilton Rating Scale for Depression 17-item (HAMD-D17) Total Score

Change From Baseline in Children's Depression Ratings Scale-Revised (CDRS-R) Total Score

Maximum Observed Plasma Concentration (Cmax)

Percentage of Participants With a Categorical Clinical Global Impressions Scales - Severity (CGI-S) Score

Percentage of Participants With a Categorical Clinical Global Impressions Scales - Improvement (CGI-I) Score

Number of Participants With Vital Sign Results of Potential Clinical Importance (PCI): Weight

Number of Participants With Vital Sign Results of Potential Clinical Importance (PCI): Pulse Rate

Number of Participants With Vital Sign Results of Potential Clinical Importance (PCI): Blood Pressure (BP)

Intervention	units on scale (Mean)
Desvenlafaxine Succinate Sustained-release (DVS SR)	1.93
Escitalopram	1.81

Intervention	units on scale (Mean)
Desvenlafaxine Succinate Sustained-release (DVS SR)	-13.63
Escitalopram	-14.30

Intervention	units on scale (Mean)
Desvenlafaxine Succinate Sustained-release (DVS SR)	0.25
Escitalopram	0.24

Intervention	units on scale (Mean)
Desvenlafaxine Succinate Sustained-release (DVS SR)	-2.09
Escitalopram	-2.22

Intervention	percentage of patients (Number)
Desvenlafaxine Succinate Sustained-release (DVS SR)	64.3
Escitalopram	73.4

Intervention	Percentage of Non-Responders (Number)
DVS SR Non-Responders / DVS SR OL	40.6
ESC Non-Responders / DVS SR OL	47.5

Intervention	units on scale (Mean)
Desvenlafaxine Succinate Sustained-release (DVS SR)	-11.37
Escitalopram	-11.73

Intervention	Percentage of Non-Responders (Number)
DVS SR Non-Responders / DVS SR OL	39.1
ESC Non-Responders / DVS SR OL	50.8

Intervention	Percentage of patients (Number)
Desvenlafaxine Succinate Sustained-release (DVS SR)	37.9
Escitalopram	48.1

Intervention	percentage of responders (Number)
DVS SR Responders / DVS SR DB	67.9
ESC Responders / ESC DB	61.3